Goldman Sachs has initiated coverage on CVS Health Corp (CVS) with a Buy rating, marking its first assessment of the company's investment potential. This decision comes as CVS operates within the health care sector, providing a range of services including health insurance products, pharmacy services, and wellness offerings. The company, headquartered in Woonsocket, Rhode Island, employs 300,000 full-time staff and has a market capitalization of $99.9 billion.
As of October 13, 2025, CVS's stock price stands at $79.84. The firm’s new rating reflects its analysis of CVS's business fundamentals and growth prospects amid evolving industry dynamics.
CVS's recent earnings performance has shown positive surprises, with Q3 2025 reporting an EPS of $1.60, exceeding estimates by 15.7%. The upcoming earnings report on July 28, 2026, is projected to yield an EPS of $2.02 on revenues of $103.7 billion.
Analyst consensus indicates a positive outlook, with 7 Strong Buy, 20 Buy, and 7 Hold ratings among 34 analysts. Such decisions reflect a range of professional opinions, which should be considered alongside company fundamentals and individual investment goals. Analyst ratings can change as new information becomes available, and differing views may exist among analysts regarding the same company.